Skip to content
★ Sign in to follow
QY

Qianjiang Yongan Pharmaceutical Co., Ltd. Stock: price and insider trades · China

永安药业

CN·Mcap CN¥3.4BHealth Care

Qianjiang Yongan Pharmaceutical Co., Ltd.: what insiders have been doing

Qianjiang Yongan Pharmaceutical Co., Ltd. has a thin disclosure history in our data (latest filing: 1 December 2025). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€99,582
1 ops. · all time

Who traded when

BuySale
方锡权1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 17,734 of 26,897 companies
41.1
score / 100
Value
33
Quality
49
FCF yld2.2%
Earn yld0.7%
EV/EBITDA27.0x
ROE2.1%
Gross mgn17%
Net mgn2.9%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥11.68
Analyst consensus
·
Income statement
RevenueCN¥783.2M
Gross profitCN¥132.5M17% margin
EBITDACN¥127.7M16% margin
Net incomeCN¥22.5M5.5% margin
Valuation
PER (trailing)64.9x
P/Book1.7x
Beta0.32
Balance sheet & cash
Market capCN¥3.4B
Total debtCN¥750k
Free Cash FlowCN¥76.8M
Debt / Equity0%
Profitability & ownership
ROE2.1%
ROA1.5%
% insiders27.7%
% institutions0.8%
Last declaration on 1 December 2025
Declarations1 total
  • ▼
    高管Executives
    817,500 CNY19SZSE
    50,000 shares100.0% of flowA股XSHESZSE:173000009853536740

1 of 1 declaration

About Qianjiang Yongan Pharmaceutical Co., Ltd.

永安药业 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of innovative medications.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations